EMA Authorised: Xeljanz (tofacitinib) — Pfizer Europe MA EEIG

View source ↗

Summary

Authorisation granted in the EU for Xeljanz (tofacitinib) for arthritis and rheumatoid conditions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arthritis
• Rheumatoid Arthritis

Drugs mentioned

• XELJANZ (tofacitinib)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Rheumatoid. MAH: Pfizer Europe MA EEIG. Decision date: 23/07/2026